BC Extra | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
BC Extra | Oct 2, 2018
Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
BC Week In Review | Jun 15, 2018
Financial News

After announced merger, TapImmune raises $70M

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 June 8 after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors...
BC Extra | Jun 8, 2018
Financial News

TapImmune shares climb on $70M offering

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 Friday after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors Aisling...
BC Week In Review | Jun 1, 2018
Company News

TapImmune, Marker Therapeutics merge

TapImmune (NASDAQ:TPIV) will merge with Marker Therapeutics Inc. (New Brighton, Minn.) to create a new cell therapy company. The merged company will use Marker Therapeutics's multi-antigen targeted cell therapy platform with TapImmune's peptide vaccine portfolio....
BC Extra | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
BC Extra | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

Immuno-oncology company TapImmune Inc. (NASDAQ:TPIV) named Peter Hoang president and CEO. He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS N.V. (Brussels, Belgium) named Ruth Devenyns CEO, a...
BC Extra | May 2, 2017
Company News

Management tracks

The Association of the British Pharmaceutical Industry named Lisa Anson president. She is president of the U.K. and Ireland division at AstraZeneca plc (LSE:AZN; NYSE:AZN). Effective June 30, President and CEO C. Randal Mills is...
BC Week In Review | Feb 16, 2017
Clinical News

TPIV 200: Ph II ongoing

An independent DSMB recommended continuation of an open-label, U.S. Phase II trial of 165 and 500 μg intradermal TPIV 200 plus GM-CSF with or without cyclophosphamide based on a safety review. Patients will receive monthly...
Items per page:
1 - 10 of 42
BC Extra | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
BC Extra | Oct 2, 2018
Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
BC Week In Review | Jun 15, 2018
Financial News

After announced merger, TapImmune raises $70M

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 June 8 after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors...
BC Extra | Jun 8, 2018
Financial News

TapImmune shares climb on $70M offering

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 Friday after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors Aisling...
BC Week In Review | Jun 1, 2018
Company News

TapImmune, Marker Therapeutics merge

TapImmune (NASDAQ:TPIV) will merge with Marker Therapeutics Inc. (New Brighton, Minn.) to create a new cell therapy company. The merged company will use Marker Therapeutics's multi-antigen targeted cell therapy platform with TapImmune's peptide vaccine portfolio....
BC Extra | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
BC Extra | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

Immuno-oncology company TapImmune Inc. (NASDAQ:TPIV) named Peter Hoang president and CEO. He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS N.V. (Brussels, Belgium) named Ruth Devenyns CEO, a...
BC Extra | May 2, 2017
Company News

Management tracks

The Association of the British Pharmaceutical Industry named Lisa Anson president. She is president of the U.K. and Ireland division at AstraZeneca plc (LSE:AZN; NYSE:AZN). Effective June 30, President and CEO C. Randal Mills is...
BC Week In Review | Feb 16, 2017
Clinical News

TPIV 200: Ph II ongoing

An independent DSMB recommended continuation of an open-label, U.S. Phase II trial of 165 and 500 μg intradermal TPIV 200 plus GM-CSF with or without cyclophosphamide based on a safety review. Patients will receive monthly...
Items per page:
1 - 10 of 42